These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38316065)

  • 1. Comprehensive biomarker diagnostics of unfavorable cancer of unknown primary to identify patients eligible for precision medical therapies.
    Zaun G; Borchert S; Metzenmacher M; Lueong S; Wiesweg M; Zaun Y; Pogorzelski M; Behrens F; Schildhaus HU; Virchow I; Kasper S; Schuler M; Theurer S; Liffers S
    Eur J Cancer; 2024 Mar; 200():113540. PubMed ID: 38316065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.
    Ross JS; Wang K; Gay L; Otto GA; White E; Iwanik K; Palmer G; Yelensky R; Lipson DM; Chmielecki J; Erlich RL; Rankin AN; Ali SM; Elvin JA; Morosini D; Miller VA; Stephens PJ
    JAMA Oncol; 2015 Apr; 1(1):40-49. PubMed ID: 26182302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.
    Westphalen CB; Federer-Gsponer J; Pauli C; Karapetyan AR; Chalabi N; Durán-Pacheco G; Beringer A; Bochtler T; Cook N; Höglander E; Jin DX; Losa F; Mileshkin L; Moch H; Ross JS; Sokol ES; Tothill RW; Krämer A
    ESMO Open; 2023 Dec; 8(6):102035. PubMed ID: 37922692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalized Therapy Selection by Integration of Molecular Cancer Classification by the 92-Gene Assay and Tumor Profiling in Patients With Cancer of Unknown Primary.
    Fuentes Bayne HE; Kasi PM; Ma L; Hart LL; Wong J; Spigel DR; Schnabel CA; Reeves JA; Halfdanarson TR; Treuner K; Greco FA
    JCO Precis Oncol; 2024 Sep; 8():e2400191. PubMed ID: 39231374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience.
    Pauli C; Bochtler T; Mileshkin L; Baciarello G; Losa F; Ross JS; Pentheroudakis G; Zarkavelis G; Yalcin S; Özgüroğlu M; Beringer A; Scarato J; Mueller-Ohldach M; Thomas M; Moch H; Krämer A
    Oncologist; 2021 May; 26(5):e769-e779. PubMed ID: 33687747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The practical utility of AI-assisted molecular profiling in the diagnosis and management of cancer of unknown primary: an updated review.
    Lorkowski SW; Dermawan JK; Rubin BP
    Virchows Arch; 2024 Feb; 484(2):369-375. PubMed ID: 37999736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress in refining the clinical management of cancer of unknown primary in the molecular era.
    Rassy E; Pavlidis N
    Nat Rev Clin Oncol; 2020 Sep; 17(9):541-554. PubMed ID: 32350398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer of Unknown Primary in the Molecular Era.
    Kato S; Alsafar A; Walavalkar V; Hainsworth J; Kurzrock R
    Trends Cancer; 2021 May; 7(5):465-477. PubMed ID: 33516660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective.
    Weiss L; Heinrich K; Zhang D; Dorman K; Rühlmann K; Hasselmann K; Klauschen F; Kumbrink J; Jung A; Rudelius M; Mock A; Ormanns S; Kunz WG; Roessler D; Beyer G; Corradini S; Heinzerling L; Haas M; von Bergwelt-Baildon M; Boeck S; Heinemann V; Westphalen CB
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8225-8234. PubMed ID: 37062035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.
    Bochtler T; Reiling A; Endris V; Hielscher T; Volckmar AL; Neumann O; Kirchner M; Budczies J; Heukamp LC; Leichsenring J; Allgäuer M; Kazdal D; Löffler H; Weichert W; Schirmacher P; Stenzinger A; Krämer A
    Int J Cancer; 2020 Jun; 146(11):3053-3064. PubMed ID: 31970771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and management of metastatic neoplasms with unknown primary.
    Bochtler T; Löffler H; Krämer A
    Semin Diagn Pathol; 2018 May; 35(3):199-206. PubMed ID: 29203116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary.
    Posner A; Sivakumaran T; Pattison A; Etemadmoghadam D; Thio N; Wood C; Fisher K; Webb S; DeFazio A; Wilcken N; Gao B; Karapetis CS; Singh M; Collins IM; Richardson G; Steer C; Warren M; Karanth N; Fellowes A; Fox SB; Hicks RJ; Schofield P; Bowtell D; Prall OWJ; Tothill RW; Mileshkin L
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36720497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site.
    Hayashi H; Kurata T; Takiguchi Y; Arai M; Takeda K; Akiyoshi K; Matsumoto K; Onoe T; Mukai H; Matsubara N; Minami H; Toyoda M; Onozawa Y; Ono A; Fujita Y; Sakai K; Koh Y; Takeuchi A; Ohashi Y; Nishio K; Nakagawa K
    J Clin Oncol; 2019 Mar; 37(7):570-579. PubMed ID: 30653423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
    Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
    Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?
    Olivier T; Fernandez E; Labidi-Galy I; Dietrich PY; Rodriguez-Bravo V; Baciarello G; Fizazi K; Patrikidou A
    Cancer Treat Rev; 2021 Jun; 97():102204. PubMed ID: 33866225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation.
    Varadhachary GR; Talantov D; Raber MN; Meng C; Hess KR; Jatkoe T; Lenzi R; Spigel DR; Wang Y; Greco FA; Abbruzzese JL; Hainsworth JD
    J Clin Oncol; 2008 Sep; 26(27):4442-8. PubMed ID: 18802157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Targeted Next-Generation Sequencing for the Management of Patients Diagnosed with a Cancer of Unknown Primary.
    Fusco MJ; Knepper TC; Balliu J; Del Cueto A; Laborde JM; Hooda SM; Brohl AS; Bui MM; Hicks JK
    Oncologist; 2022 Feb; 27(1):e9-e17. PubMed ID: 35305098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New techniques to identify the tissue of origin for cancer of unknown primary in the era of precision medicine: progress and challenges.
    Ma W; Wu H; Chen Y; Xu H; Jiang J; Du B; Wan M; Ma X; Chen X; Lin L; Su X; Bao X; Shen Y; Xu N; Ruan J; Jiang H; Ding Y
    Brief Bioinform; 2024 Jan; 25(2):. PubMed ID: 38343328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary.
    Moran S; Martinez-Cardús A; Boussios S; Esteller M
    Nat Rev Clin Oncol; 2017 Nov; 14(11):682-694. PubMed ID: 28675165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: analysis of 1806 cases.
    Gatalica Z; Millis SZ; Vranic S; Bender R; Basu GD; Voss A; Von Hoff DD
    Oncotarget; 2014 Dec; 5(23):12440-7. PubMed ID: 25415047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.